XML 48 R37.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended
May 06, 2016
Dec. 24, 2018
Sep. 30, 2017
Sep. 25, 2017
Jul. 24, 2017
May 26, 2017
Aug. 31, 2016
Jul. 27, 2016
Dec. 31, 2015
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Collaborative Agreements (Textual)                          
Common stock newly issued, value                   $ 694,219 $ 80,000    
Outstanding balance                   58,225   $ 59,477  
Collaborative Arrangement [Member]                          
Collaborative Agreements (Textual)                          
Amount received from BriVision         $ 3,000,000                
Percentage of payments under co-development agreement         50.00%                
Common stock newly issued, value $ 900,000       $ 3,000,000                
Licensing rights       $ 3,000,000                  
Accounts payable                   $ 15,000,000      
Research and development expense       $ 3,000,000                  
Co-Dev Agreement [Member]                          
Collaborative Agreements (Textual)                          
Amount received from BriVision     $ 3,000,000     $ 3,000,000             $ 450,000
Percentage of payments under co-development agreement           50.00%              
Company cash payments     $ 3,000,000     $ 3,000,000              
Co-Dev agreement, description   The Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene's Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                      
BHK Co-Development Agreement [Member]                          
Collaborative Agreements (Textual)                          
Description of payment settlement               Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment At the completion of first phase II clinical trial: $1 million, or 10% of total payment At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment          
Upfront payments               $ 1,000,000 $ 1,000,000        
Percentage of payments under co-development agreement               10.00% 10.00%        
Milestone payments to BioLite in cash             $ 31,649,000 $ 10,000,000          
Common stock newly issued, value             $ 1,000,000   $ 10,000,000        
Milestone payments royalty percentage             12.00%            
Collaborative Agreements, description                 The Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March 31, 2019 and 2018, the Company has not earned the royalty under the BHK Collaborative Agreements.